Some practical considerations for phase III studies with biomarker evaluations
J Clin Oncol
.
2014 Mar 10;32(8):854-5.
doi: 10.1200/JCO.2013.53.7613.
Epub 2014 Feb 3.
Authors
Sasikiran Goteti
1
,
Samit Hirawat
,
Cristian Massacesi
,
Nathalie Fretault
,
Frank Bretz
,
Bharani Dharan
Affiliation
1
Novartis Pharmaceuticals, East Hanover, NJ.
PMID:
24493715
DOI:
10.1200/JCO.2013.53.7613
No abstract available
Publication types
Letter
Comment
MeSH terms
Biomarkers, Tumor / analysis*
Clinical Trials, Phase III as Topic*
Humans
Neoplasms / drug therapy*
Research Design*
Substances
Biomarkers, Tumor